Polyrizon Ltd. Ordinary Shares (PLRZ) - Total Assets
Based on the latest financial reports, Polyrizon Ltd. Ordinary Shares (PLRZ) holds total assets worth $18.74 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Polyrizon Ltd. Ordinary Shares (PLRZ) net asset quality to measure how much of total assets are equity-financed.
Polyrizon Ltd. Ordinary Shares - Total Assets Trend (2020–2024)
This chart illustrates how Polyrizon Ltd. Ordinary Shares's total assets have evolved over time, based on quarterly financial data. Check Polyrizon Ltd. Ordinary Shares tangible book value ratio to evaluate the tangible quality of the company's equity base.
Polyrizon Ltd. Ordinary Shares - Asset Composition Analysis
Current Asset Composition (December 2024)
Polyrizon Ltd. Ordinary Shares's total assets of $18.74 Million consist of 47.8% current assets and 52.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 46.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.88 Million | 52.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Polyrizon Ltd. Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PLRZ company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Polyrizon Ltd. Ordinary Shares's current assets represent 47.8% of total assets in 2024, a decrease from 79.2% in 2020.
- Cash Position: Cash and equivalents constituted 46.0% of total assets in 2024, up from 41.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 52.0% of total assets.
Polyrizon Ltd. Ordinary Shares Competitors by Total Assets
Key competitors of Polyrizon Ltd. Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Polyrizon Ltd. Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 44.04 | 0.12 | 2.38 |
| Quick Ratio | 44.04 | 0.12 | 2.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.67 Million | $-321.00K | $11.00K |
Polyrizon Ltd. Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Polyrizon Ltd. Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.82 |
| Latest Market Cap to Assets Ratio | 2.48 |
| Asset Growth Rate (YoY) | 892.3% |
| Total Assets | $5.55 Million |
| Market Capitalization | $13.78 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Polyrizon Ltd. Ordinary Shares's assets at a significant premium (2.48x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Polyrizon Ltd. Ordinary Shares's assets grew by 892.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Polyrizon Ltd. Ordinary Shares (2020–2024)
The table below shows the annual total assets of Polyrizon Ltd. Ordinary Shares from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.55 Million | +892.31% |
| 2023-12-31 | $559.00K | +2.38% |
| 2022-12-31 | $546.00K | -20.52% |
| 2021-12-31 | $687.00K | +2762.50% |
| 2020-12-31 | $24.00K | -- |
About Polyrizon Ltd. Ordinary Shares
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nas… Read more